Clinical Report: Effectiveness and Safety of Vismodegib for BCC
Overview
Revise to specify the patient population and context of the complete response rate.
Background
Periocular and orbital BCC poses significant treatment challenges due to its location near critical structures and the risk of disfigurement. Vismodegib, a Hedgehog pathway inhibitor, offers a non-surgical treatment option, but its effectiveness and tolerability in this specific patient population require thorough evaluation. Understanding the outcomes associated with vismodegib is crucial for optimizing management strategies in patients with advanced BCC.
Data Highlights
Outcome
Pooled Rate (95% CI)
Complete Response Rate
38.4% (36.6–57.4)
Partial Response Rate
39.2% (32.4–47.5)
Recurrence Rate
17.4% (7.0–30.3)
Exenteration Rate
28.1% (12.3–34.5)
Adverse Events
90.3% (81.0–94.8)
Severe Adverse Events (Grade ≥3)
25.5%
Key Findings
The pooled complete response rate for vismodegib in periocular and orbital BCC was 38.4%.
Partial response was observed in 39.2% of patients.
Recurrence after treatment discontinuation occurred in 17.4% of cases.
Exenteration was necessary in 28.1% of patients despite vismodegib therapy.
Adverse events were reported in 90.3% of patients, with common events including alopecia and muscle spasms.
31.2% of patients discontinued treatment due to toxicity.
Clinical Implications
Clinicians should consider vismodegib as a viable treatment option for patients with periocular and orbital BCC, particularly when surgical options are limited. However, the high rates of adverse events and recurrence necessitate careful patient selection and ongoing monitoring to manage potential complications effectively.
Conclusion
Vismodegib demonstrates significant tumor regression in periocular and orbital BCC, but the associated adverse events and recurrence rates highlight the importance of judicious use and patient management.
